English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduWistar scientists have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells.
Tag: Melanoma
Immunology study finds protein critical to T cell metabolism and anti-tumor immune response
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is essential for the shift in metabolic activity that occurs with T cell activation, making it a critical factor in regulating the anti-tumor immune response.
Weizmann Institute of Science and Colleagues Show How Cancer Cells Hurt Themselves to Hurt Immune Cells More
Melanoma is skilled at evading therapies, with its cells going so far as to starve in order to stop the immune cells that would eradicate them. A team from the Weizmann Institute, including Prof. Yardena Samuels; the Netherlands Cancer Institute; and the University of Oslo have revealed one of melanoma’s tricks – never before seen in human cells – and a therapeutic target.
New combination therapy could help fight difficult-to-treat cancers with common mutations
UCLA scientists describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. This combination of two small molecules has the potential to treat not only BRAF mutated melanoma but also additional aggressive subtypes of cancers, including melanoma, lung, pancreatic and colon cancers that harbor common mutations in cancer genes called RAS or NF1.
Cancer cases are rising in adolescents and young adults
Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine.
A Conversation With a Living Legend honoring Admiral William H. McRaven raises $1 million
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting The University of Texas
MD Anderson Cancer Center. The 31st annual event honored Admiral William H. McRaven, U.S. Navy, Retired, in an interview Nov. 16 with CBS News’ Bob Schieffer. Proceeds will benefit MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
Mount Sinai Researchers Discover How to Boost Efficacy of Vaccine Designed to Prevent Melanoma Recurrence
A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November.
Study identifies patients with lung cancer most likely to respond to immunotherapy
Researchers at the UCLA Jonsson Comprehensive Cancer Center found patients with a particular type of human leukocyte antigen (HLA), a protein scaffold involved in presenting pieces of proteins described as peptides to the immune system, were particularly likely to benefit from immunotherapy.
Smilow Cancer Hospital Receives CT Lions Eye Research Foundation Grant to Study Eye Cancer
The Connecticut Lions Eye Research Foundation has awarded a grant to Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center.
MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .
Plastic Surgeon Matthew S. Coons, M.D., FACS Joins Hackensack Meridian Mountainside Medical Group
Mountainside Medical Group announced today that plastic surgeon Matthew S. Coons, M.D., FACS, has joined the practice.
Dr. Coons is board certified by the American Board of Surgery and the American Board of Plastic Surgery. His interests also include hand surgery and reconstructive surgery with an emphasis on breast reconstruction.
FLORIDA DERMATOLOGIST RECOGNIZED FOR TREATMENT OF VIETNAM VETERAN
The American Academy of Dermatology named board-certified dermatologist Cyndi Yag-Howard, MD, FAAD, a Patient Care Hero for her work treating veterans with serious service-related skin conditions.
UCLA physician-scientist elected to National Academy of Medicine
Dr. Antoni Ribas, a world-renowned physician–scientist and professor of medicine at the David Geffen School of Medicine at UCLA, has been named to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.
Virus-mimicking drug helps immune system target cunning cancer cells
UCLA researchers have found that a drug that activates the body’s natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.
UCLA researchers’ efforts to combat melanoma gets $13M boost from NIH
UCLA researchers have received a $13 million grant from the National Institutes of Health to find new ways to overcome melanoma resistance to some of the most promising targeted therapies and immunotherapies.
Scientists kill cancer cells by “shutting the door” to the nucleus
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that blocking the construction of nuclear pores complexes—large channels that control the flow of materials in and out of the cell nucleus—shrank aggressive tumors in mice while leaving healthy cells unharmed. The study, published in Cancer Discovery, a journal of the American Association for Cancer Research, reveals a new Achilles heel for cancer that may lead to better treatments for deadly tumors such as melanoma, leukemia and colorectal cancer.
Cancer Research Institute Goes Virtual for Its Immunotherapy Patient Summit Series, Connecting Patients and Caregivers with Leading Experts in Cancer Immunotherapy
Free virtual event October 2-3 connecting cancer patients and caregivers with leading immunotherapy experts and patient advocates treated with immunotherapy
UCLA study shows how interferon-gamma guides response to cancer immunotherapy
UCLA researchers shed light on how interferon-gamma (IFN-y) guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies — immune checkpoint blockade.
Leading Cancer Treatment Recommendations from NCCN Now Available in French, German, Italian, Portuguese, Russian, and Spanish
NCCN Guidelines, containing expert recommendations for cancer care, are available in French, German, Italian, Portuguese, Russian, and Spanish can all be accessed for free at NCCN.org/global or via the free Virtual Library of NCCN Guidelines® App
Moffitt Researchers Identify Driver of Further Metastasis in BRAF Inhibitor Resistant Melanoma
In a new article published in the Journal of Investigative Dermatology, Moffitt researchers identify erythropoietin-producing hepatocellular receptor A2 (EphA2) as a driver of metastasis and BRAF-MEK inhibitor resistance in melanoma.
The Secret of Lymph: How Lymph Nodes Help Cancer Cells Spread
August 19, 2020 (DALLAS, TEXAS) – For decades, physicians have known that many kinds of cancer cells often spread first to lymph nodes before traveling to distant organs through the bloodstream. New research from Children’s Medical Center Research Institute at UT Southwestern (CRI) provides insight into why this occurs, opening up new targets for treatments that could inhibit the spread of cancer.
Researchers Outline Need for Further Evaluation of Gene Expression Profiling in Melanoma Patients
A consensus statement published today in JAMA Dermatology by a group of melanoma researchers evaluates the use of prognostic genetic expression profiling within clinical treatment of patients with melanoma. The group cautioned against routine use of currently-available genetic expression profiling tests for patients with cutaneous melanoma.
Use of Pembrolizumab Provided Long-Term Benefits in Patients With Metastatic Melanoma, 10-Year Look Shows
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (brand name Keytruda) in patients with advanced melanoma.
A helping hand for cancer immunotherapy
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently in clinical trials in oncology, and this research provides a strong rationale for evaluating the drugs in tumors that are not responsive to immune checkpoint therapy. The study was published in Science Translational Medicine.
Telemedicine helps Missouri dermatologist detect melanoma
The American Academy of Dermatology (AAD) has named board-certified dermatologist Kari Lyn Martin, MD, FAAD, a Patient Care Hero for using telemedicine to diagnose and remove a patient’s melanoma the same day.
Expert in Early Phase Therapeutics Joins NYU Langone Health as Associate Director for Clinical Research at Perlmutter Cancer Center
Janice M. Mehnert, MD, a nationally recognized expert in early phase therapeutics and the treatment of skin malignancies, has been appointed associate director for clinical research at NYU Langone Health’s Perlmutter Cancer Center. She assumes her post July 1, 2020.
WHAT TO WEAR TO PROTECT YOUR SKIN FROM THE SUN
Skin cancer is the most common cancer in the U.S., and nearly 20 Americans die from melanoma, the deadliest form of skin cancer, every day. As more Americans prepare to head outdoors for the 4th of July holiday, dermatologists from the American Academy of Dermatology have an important reminder: dress to protect yourself from the sun. In addition to seeking shade and applying sunscreen, wearing protective clothing goes a long way in protecting you from the sun’s harmful UV rays, which can increase your risk of skin cancer. However, not all clothing is created equal when it comes to sun protection, say dermatologists. Some garments provide better UV protection than others.
NEW AAD SURVEY: 74% OF PARENTS TODAY SAY THEY WORRY ABOUT SUN PROTECTION MORE WITH THEIR CHILDREN THAN THEIR PARENTS DID WITH THEM
With Father’s Day approaching, dermatologists are giving parents two thumbs up for keeping sun protection top of mind for their families. According to a new survey from the American Academy of Dermatology, 74% of parents today say they worry about sun protection more with their children than their parents did with them, and 90% of parents believe it’s important to teach their children healthy habits now so they will keep them when they are adults.
Memorial Sloan Kettering Awards & Appointments
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
MSK: Cancer Isn’t Sheltering in Place
As the height of the COVID-19 outbreak in New York City and the Tri-State area begins to subside, Memorial Sloan Kettering Cancer Center oncologists are urging patients to schedule cancer screenings and treatments now – as the long-term toll of missed diagnoses and delayed treatments could be devastating for patients and their loved ones across the region and the country.
SURVEY: 60% OF AMERICANS SAY THEY HAVE GOTTEN SUNBURNED SO BADLY THEIR CLOTHES WERE UNCOMFORTABLE
Memorial Day — long considered the unofficial start of summer in the U.S. — is quickly approaching, and dermatologists from the American Academy of Dermatology are urging Americans to practice safe sun as they head outdoors, especially as shelter-in-place measures related to COVID-19 begin to lift. Skin cancer is the most common cancer in the U.S., affecting one in five Americans in their lifetime, yet new data from the AAD shows that many Americans aren’t protecting themselves from the sun’s harmful ultraviolet (UV) rays.
Study finds racial differences in time it takes to treat melanoma
Black patients with one of the deadliest forms of skin cancer are likely to experience a longer delay from diagnosis to surgery than non-Hispanic white (NHW) patients, according to a new study published in the Journal of the American Academy of Dermatology.
GW Dermatology Experts Available to Speak During Skin Cancer Awareness Month
WASHINGTON (April 28, 2020) — Skin cancer is one of the most common types of cancers, with 1 in 5 Americans developing it by the age of 70 and representing 1% of all cancer-related deaths according to the National Cancer…
NEW AMERICAN ACADEMY OF DERMATOLOGY SURVEY FINDS MOST AMERICANS KNOW SUN PROTECTION IS IMPORTANT, YET MANY AREN’T PROTECTING THEMSELVES
As more Americans head outdoors for warmer weather and fresh air amid “shelter-in-place” measures, dermatologists from the American Academy of Dermatology have an important reminder: practice safe sun. Skin cancer is one of the most preventable types of cancer, but new data from the AAD shows that many Americans aren’t taking the necessary steps to protect themselves.
Superior Progression-Free Survival Associated with Continuous Targeted Therapy Combination for BRAF-mutated Melanoma
Results from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.
American Academy of Dermatology Statement on the Dangers of Ultraviolet Exposure
There is no evidence to support the recent speculation that traditional ultraviolet exposure is an effective treatment for COVID-19. This misinformation may encourage the public to seek UV radiation from the sun and tanning beds, inherently increasing their risk of skin cancer.
Combination creates powerful central memory T cells for cellular therapy
MD Anderson researchers find that treating T cells with panobinostat and IL-21 re-programs them to a powerful central memory T cell type that persists longer.
Melanoma Is Killing Fewest Americans in Decades
Advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded for this skin cancer, results of a new study suggest.
Still a fan of the golden tan? Tune in to social media and tone down your risk of skin cancer
Social media smarts could make you less susceptible to skin cancer as new research shows that media literacy skills can help change people’s attitudes about what is believed to be the ‘tanned ideal’.
Study identifies states with highest rates of melanoma due to ultraviolet radiation
A new study finds a wide state-by-state variation in rates of melanoma caused by ultraviolet (UV) exposure with highest rates in several states on the East and West Coast including Hawaii, but also a few landlocked states, including Utah, Vermont, and Minnesota.
Prebiotics help mice fight melanoma by activating anti-tumor immunity
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two prebiotics, mucin and inulin, slowed the growth of melanoma in mice by boosting the immune system’s ability to fight cancer. The study, published today in Cell Reports, provides further evidence that gut microbes have a role in shaping the immune response to cancer, and supports efforts to target the gut microbiome to enhance the efficacy of cancer therapy.
Skin Cancer Screening in Taos
The UNM Department of Dermatology and the UNM Comprehensive Cancer Center are hosting free skin cancer screenings around the state to address the state’s dermatologist shortage. The next screening clinic will take place in Taos, N.M., on Feb. 29.
Cold plasma patch could make immunotherapy more effective for treating melanoma, study finds
An interdisciplinary team of researchers at the UCLA Jonsson Comprehensive Cancer Center has developed a medicated patch that can deliver immune checkpoint inhibitors and cold plasma directly to tumors to help boost the immune response and kill cancer cells.
Study demonstrates liquid biopsy as effective predictor of stage III melanoma relapse and treatment
A study at The University of Texas MD Anderson Cancer Center showed that circulating tumor cells (CTCs), a form of liquid biopsy, was independently associated with melanoma relapse, suggesting CTC assessment may be useful in identifying patients at risk for relapse who could benefit from more aggressive therapy following primary treatment.
Researchers identify possible new combination treatment for advanced melanoma
Using an immunotherapy drug in combination with an infusion of anti-tumor immune cells may produce a stronger immune response that could help fight advanced melanoma.
Fighting melanoma with zebrafish: Biologists in search of a powerful combination of cancer-fighting drugs
Northern Arizona University professor Matthew Salanga is leading an 18-month project, funded by the Flinn Foundation, in search of drugs to help fight the deadliest form of skin cancer.
Study finds 95 percent satisfaction rate with Mohs surgery
Survey of more than 40 UT Southwestern patients reveals positive outcomes
Study reveals a new approach to enhancing response to immunotherapy in melanoma
Scientists at Sanford Burnham Prebys have identified a new way to boost the immune system’s ability to fight cancer. The study used a mouse model to identify the importance of the Siah2 protein in the control of immune cells called T regulatory cells (Tregs), which limit the effectiveness of currently used immunotherapies. The research, which offers a new avenue to pursue immunotherapy in cases where the treatment fails, was published today in Nature Communications.
CRI scientists discover metabolic feature that allows melanoma cells to spread
Researchers at Children’s Medical Center Research Institute at UT Southwestern (CRI) have uncovered why certain melanoma cells are more likely to spread through the body.
One-two punch drug combination offers hope for pancreatic cancer therapy
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice—supporting the immediate evaluation of the drugs in a clinical trial. U.S. Food and Drug Administration (FDA)–approved versions of the compounds are used today to treat certain leukemias and solid tumors, including melanoma. The study was published in Nature Cell Biology.